Melvin L.K. Chua: The massive disparities in global radiotherapy demands

Melvin L.K. Chua shared a post on X:

“This is excellent work led by Hongcheng Zhu showcasing the massive disparities in global RT Radiotherapy demands including bold predictions for staff training!

Important to put the message out there!”

Global radiotherapy demands and corresponding radiotherapy-professional workforce requirements in 2022 and predicted to 2050: a population-based study

Authors: Hongcheng Zhu, et al.

Dr. Melvin L.K. Chuaam is  a Clinician-Scientist at the NCCS and Duke-NUS Medical School, and Principal Investigator of the Precision Radiotherapeutics and Oncology Programme, Division of Medical Sciences, supported by the NMRC Clinician-Scientist Award. He is also the Head of Department and Senior Consultant for Head and Neck and Thoracic Cancers, Division of Radiation Oncology, and Director of the Data and Computational Science Core at the NCCS. His research is focused on phase 2-3 trials in nasopharynx (NPC) and prostate cancers (PCa).

He is also on the scientific advisory board for the NPC Guangzhou-Singapore Trial Network, a board member on the Head Neck Cancer International Group (HNCIG), and the Clinical Trials Scientific Committee Chair of HNCIG. Dr. Chuaam’s other academic activities include his present role as the Editor-in-Chief, Annals of Nasopharynx Cancer and his previous role as the Associate Senior Editor for the Head and Neck Cancer Section of the International Journal of Radiation Oncology Biology Physics – Official journal of the American Society of Radiation Oncology.